Valldeoriola, FrancescCatalán, María JoséEscamilla-Sevilla, FranciscoFreire, EricOlivares, JesúsCubo, EstherGarcía, Diego SantosCalopa, MatildeMartínez-Martín, PabloParra, Juan CarlosArroyo, GloriaArbelo, José Matías2025-01-072025-01-072021-11-302373-8057https://hdl.handle.net/10668/24983Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/research article34848716open access10.1038/s41531-021-00246-yPMC8633325https://www.nature.com/articles/s41531-021-00246-y.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8633325/pdf